WebMD, QualityHealth.com merger terminated

Share this article:

A merger between WebMD and Marketing Technology Solutions (MTS) – the parent of QualityHealth.com – has been terminated.

The $50 million merger, announced in mid-September, had been expected to be finalized by Oct. 15. Instead, WebMD has “acquired a minority preferred interest in MTS,” the statement said. Financial terms were not disclosed. A spokesperson for WebMD declined to comment on the details of the failed merger.

WebMD also entered into an advertising services agreement with QualityHealth.com, allowing WebMD to represent a portion of QualityHealth.com's media inventory. Conversely, QualityHealth.com will have limited access to certain parts of WebMD's inventory, according to the spokesperson. QualityHealth.com was not immediately available for comment.

Following a merger with Revolution Health, Waterfront Media's Everyday Health Network topped WebMD in terms of unique visitors for October, according to comScore data. WebMD had previously led the category for nearly 10 years. QualityHealth.com ranked eighth in unique visitors for October, at 7.3 million. Had the WebMD, QualtyHealth.com merger gone through, WebMD would have been in a position to rival Everyday Health's unique visitor count, and possibly exceed it.

The WebMD Network includes WebMD Health, Medscape, MedicineNet, eMedicine, eMedicine Health, RxList and theHeart.org.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.